BeyondSpring (NASDAQ:BYSI) Shares Down 4%

BeyondSpring Inc. (NASDAQ:BYSIGet Rating)’s share price traded down 4% during trading on Thursday . The stock traded as low as $1.14 and last traded at $1.20. 143,728 shares traded hands during trading, a decline of 60% from the average session volume of 359,108 shares. The stock had previously closed at $1.25.

BeyondSpring Stock Performance

The company has a 50-day moving average of $1.43 and a 200 day moving average of $1.64. The firm has a market cap of $46.71 million, a P/E ratio of -0.73 and a beta of 1.03.

Hedge Funds Weigh In On BeyondSpring

Several institutional investors have recently bought and sold shares of BYSI. BNP Paribas Arbitrage SA raised its position in BeyondSpring by 2,749.1% in the 4th quarter. BNP Paribas Arbitrage SA now owns 109,890 shares of the company’s stock valued at $498,000 after purchasing an additional 106,033 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of BeyondSpring in the 4th quarter valued at $83,000. Hennion & Walsh Asset Management Inc. increased its stake in shares of BeyondSpring by 65.2% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 84,408 shares of the company’s stock valued at $186,000 after buying an additional 33,325 shares during the period. Decheng Capital Management III Cayman LLC acquired a new stake in shares of BeyondSpring in the 1st quarter valued at $10,908,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of BeyondSpring in the 1st quarter valued at $76,000. Institutional investors own 23.35% of the company’s stock.

About BeyondSpring

(Get Rating)

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.

Recommended Stories

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.